Antifungal Activity of Hydroalcoholic Extract of Chrysobalanus icaco Against Oral Clinical Isolates of Candida Species

João Paulo Bastos Silva¹, Ana Regina Maués Noronha Peres¹, Thiago Portal Paixão¹, Andressa Santa Brígida Silva², Ana Cristina Baetas¹, Wagner Luiz Ramos Barbosa¹,², Marta Chagas Monteiro¹, Marcieni Ataíde Andrade¹

¹Graduate Program in Pharmaceutical Sciences, Institute of Health Sciences, Federal University of Pará, Belém, ²Pharmaceutical Innovation Graduate Program, Institute of Health Sciences, Federal University of Pará, Belém, Pará, Brazil

ABSTRACT

Background: Chrysobalanus icaco is a medicinal plant commonly used to treat fungal infections in Brazilian Amazonian region. Objective: This work aimed to evaluate the antifungal activity of the hydroalcoholic extract of C. icaco (HECi) against oral clinical isolates of Candida spp. and to determine the pharmacognostic parameters of the herbal drug and the phytochemical characteristics of HECi. Materials and Methods: The pharmacognostic characterization was performed using pharmacopeial techniques. Phytochemical screening, total flavonoid content, and high-performance liquid chromatography (HPLC) analysis were used to investigate the chemical composition of the HECi. A broth microdilution method was used to determine the antifungal activity of the extract against 11 oral clinical isolates of Candida spp. Results: Herbal drug presented parameters which were within the limits set forth in current Brazilian legislation. A high amount of flavonoid content (132.959.33 ± 12.598.23 µg quercetin equivalent/g of extract) was found in HECi. Flavonoids such as myricetin and rutin were detected in the extract by HPLC analyses. HECi showed antifungal activity against oral isolates of Candida albicans and Candida parapsilosis (minimum inhibitory concentrations [MIC] 3.12 and 6.25 mg/mL, respectively), and C. albicans American American Type Culture Collection (MIC <1.56 mg/mL).

Conclusion: HECi was shown to possess antifungal activity against Candida species with clinical importance in the development of oral candidiasis, and these activities may be related to its chemical composition. The antifungal activity detected for C. icaco against Candida species with clinical importance in the development of oral candidiasis can be attributed to the presence of flavonoids in HECi, characterized by chromatographic and spectroscopic techniques.

Key words: Antifungal activity, Candida spp., Chrysobalanus icaco, flavonoids, myricetin, rutin

SUMMARY

• Chrysobalanus icaco presents a high amount of flavonoids in its constitution
• LC analysis was able to identify the flavonoids myricetin and rutin in C. icaco hydroalcoholic extract
• The C. icaco hydroalcoholic extract inhibits the growth of oral clinical isolates of Candida spp. and Candida albicans American Type Culture Collection

Abbreviations Used: HECi: Hydroalcoholic extract of C. icaco; HPLC: High performance liquid chromatography; LC: liquid chromatography; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Microbroth: Microtiter plates; DMSO: Dimethyl sulfoxide; CH3NOONa: Sodium acetate; HCl: Hydrochloric acid; AlCl3: Aluminum chloride; ATCC: American Type Culture Collection; EMBRAPA: Brazilian Agricultural Research Corporation – Eastern Amazon; v/v: Volume per volume; SD: Standard deviation; TFC: Total flavonoid content; w/w: Weight per weight; ELSD: Evaporative light scattering detector; DAD: Diode-arrange detector; UFPA: Federal University of Pará; IEC: Evandro Chagas Institute; INGOQ—FIORestr: National Institute of Quality Control in Health – Fundação Oswaldo Cruz; SDA: Sabouraud Dextrose Agar; CFU: Colony-forming unit; MIC: Minimum inhibitory concentrations; MFC: Minimum fungicidal concentrations

Correspondence: Prof. Marcieni Ataíde de Andrade (Ph.D.), Graduate Program in Pharmaceutical Sciences, Institute of Health Sciences, Federal University of Pará - Augusto Corrêa Street, Number 01, Postal Code 66075 110, Belém, Pará, Brazil. E-mail: marcieni@ufpa.br

DOI: 10.4103/0974-8490.199772

INTRODUCTION

Candidiasis is currently considered one of the most common fungal infections that affect humans. This disease is caused by saprophytic Candida spp. yeasts that inhabit the oral mucosa of healthy individuals.¹ However, factors such as immunosuppression, long-term use of broad-spectrum antibiotics and xerostomia may trigger to a alteration in host homeostasis, and consequently the development of pathogenic forms of the fungus.² The topical and systemic antifungal agents of the polyene or azole family are commonly used to the management of oral candidiasis.³,⁴

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Cite this article as: Silva JP, Peres AM, Paixão TP, Silva AS, Baetas AC, Barbosa WL, et al. Antifungal activity of hydroalcoholic extract of Chrysobalanus icaco against oral clinical isolates of Candida Species. Phcog Res 2017;9:96-100.
Although the treatment with these antifungal drugs presents relative effectiveness, most of them can cause undesirable side effects such as gastrointestinal disorders, hepatotoxicity, hair loss, visual disturbances, among others, and also the emergence of drug-resistant strains of Candida spp.[6]

Chrysobalanus icaco L. (Chrysobalanaceae) is a shrub largely used in folk traditional phytotherapy to treat fungal infections in the Amazonian region.[8] This medicinal plant occurs naturally in South Florida, Caribbean, Central America, Northwestern of South America, and tropical West Africa.[5] Phytochemical studies have revealed the presence of flavonoids, including quercetin, myricetin, and its derivatives in a hydroalcoholic extract of leaves.[8] Stigmasterol, sitosterol, campesterol, pomolic acid, and a kaempferol derivative were identified in a hexane extract of leaves and their fractions.[9] Anthocyanins and terpenes were also found in C. icaco extracts.[10,11]

Regarding their biological properties, C. icaco possess anti-inflammatory, antimicrobial, analgesic, anti-diabetic, and anticancer activities[9,12] beyond prevent fat gain in obese high-fat fed mice.[13] Although the antimicrobial activity of this plant has been previously reported, there are no data about the effect of C. icaco against oral clinical isolates of Candida spp., often related to the emergence of fungal infections in the oral cavity. Thus, the aim of this work was to evaluate the in vitro antifungal activity of C. icaco against clinical isolates of Candida spp. and to determine the phytochemical profile of hydroalcoholic extract of C. icaco (HECi) by high-performance liquid chromatography (HPLC) and the pharmacognostic parameters of the herbal drug.

MATERIALS AND METHODS

Chemicals and reagents
Acetonitrile (Fluka, USA), methanol (Tedia Company Inc., USA), formic acid (Vetec, Duque de Caxias, Brazil), aluminum chloride (AlCl₃), dimethyl sulfoxide (DMSO), ethanol (Synth, Brazil), sodium acetate (J.T. Baker, Mexico), nystatin, chloramphenicol, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), quercetin, myricetin, and rutin (Sigma-Aldrich, St. Louis, MO, USA). The medium Sabouraud Dextrose Agar (SDA), Mueller-Hinton agar, and Mueller-Hinton broth were purchased from Himedia Laboratories (Mumbai, India).

Plant material and herbal drug preparation
C. icaco leaves (2.3 kg) were collected in Salinópolis, Northeast Pará, Brazil (0°36'1,76" S/47°18'11,70" W) in October 2010. A voucher specimen was prepared and identified by a specialist of the Herbarium of the Brazilian Agricultural Research Corporation – Eastern Amazon (EMBRAPA) and registered under the number: NID 40/2011. After collection, the leaves were washed with tap water, cleaned with a hydroalcoholic solution (70%, v/v), air-dried for 5 days and subsequently in an air-forced oven (–40°C) for 2 days. C. icaco dried leaves (1.16 kg) were then ground in a knife mill.

Pharmacognostic characterization of Chrysobalanus icaco herbal drug
To characterize the herbal drug obtained from C. icaco leaves, the following determinations were performed: Granulometric analysis, foaming index, loss on drying, total ash and acid-insoluble ash contents, bulk density, apparent relative density, and content of extractable matter.[14,15] All the experiments were carried out in triplicate, and the results are expressed as a mean ± standard deviation.

Extraction procedure
The herbal drug of C. icaco (200 g) was successively extracted by maceration with a hydroethanolic mixture (70%, v/v) for 7 days. Then, both the extracts were filtered, combined, and evaporated under reduced pressure (40°C, 167 mbar, and 120 rpm) to provide 32.49 g of crude HECi, whose yield was 16.24% and 8.19% in relation to the herbal drug and fresh plant, respectively.

Preliminary phytochemical screening
Qualitative tests were performed in HECi to detect the following metabolic classes: Reducer sugars, alkaloids, carotenoids, coumarin, depside and depsidone, steroids and triterpenoids, tannins, flavonoids, cardiac glycosides, proteins and amino acids, saponin, and sesquiterpene lactones.[16]

Total flavonoid content
Total flavonoid content (TFC) was determined using aluminum complexation reaction as described by Pękal and Pyrzynska.[17] In brief, 0.5 mL of an AlCl₃ solution (2%, w/v) was added to 1 mL of HECi dissolved in methanol (2.5 mg/mL) and subsequently 0.5 mL of CH₃COONa solution (1M) was added. The resulting mixture was vigorously shaken and was allowed to react for 10 min at room temperature. After incubation, the absorbance was measured at 425 nm. A blank solution consisted in the above-mentioned mixture where distilled water replaces the same volume of AlCl₃. The TFC was calculated using a calibration curve of quercetin (the linearity range: 0.07–1.17 µg/mL, equation: y = 0.4944x – 0.002, R² = 0.9958) and expressed as µg quercetin equivalents/g of HECi. All determinations were carried out in triplicate.

High-performance liquid chromatography analysis of hydroalcoholic extract of Chrysobalanus icaco
Chromatographic analyses were performed in the Laboratory of Chromatography and Mass Spectrometry Faculty of Pharmacy, UFPA (Belém, Pará, Brazil) using an Agilent Technologies 1260 HPLC chromatograph (Agilent, USA) coupled to an evaporative light scattering detector (Agilent, USA) and a diode-arrange detector (Agilent, USA) working between 190 and 400 nm with monitoring at 260 nm. The ELSD detector was warmed up for 30 min before each run, using as evaporation and nebulization temperatures, 85°C and 40°C, respectively, and an optimum flow rate of 1.6 L/min nitrogen, 99.99%, as nebulizing gas. A Zorbax Eclipse XDB C18 (150 mm × 4.6 mm × 5 µm) column used was maintained at 26°C. Acetonitrile (a) and aqueous formic acid, pH 3 (b) composed the mobile phase in the following gradient: 5%–15% A (0–5 min), 15%–25% A (5–25 min), isocratic at 25% A (25–40 min), and 25%–5% A (40–45 min), which was pumped at a flow of 1.0 mL/min. The injection volume was 20 µL. Data were produced and processed using Open Lab software on a HP Z220 computer.

In vitro antifungal activity
Obtaining clinical isolates of oral cavity
The study was approved by the Research Ethics Committee of UFPA (CAAE 0051.0.073.000-11, Registry 060/11 CEP-ICS/UFPA). Clinical isolates were collected from oral cavity of healthy patients (both sexes between 18 and 59 years old, nondiabetics, nonimmunosuppressed, nonusers of antibiotics and/or immunosuppressive drugs, and nondrug-abusing) undergoing dental clinical treatment at the Faculty of Dentistry, UFPA (Belém, Pará, Brazil), with the help of a sterile swab as described previously.[18] A total of 11 Candida spp. clinical isolates were obtained and subsequently identified in the Evandro Chagas Institute.
Antifungal activity of hydroalcoholic extract of Chrysobalanus icaco

Antifungal activity of the HECi against oral clinical isolates of Candida spp. was determined by broth microdilution method according to protocol M27-A3 of the Clinical and Laboratory Standards Institute, with minor modifications by de Quadros et al.\(^\text{[19,20]}\) To obtain the inoculums, 3–4 colonies of each species of Candida spp. measuring ~1 mm, previously subcultured in ASD medium and incubated for 24 h at 25°C, were suspended in sterile saline (2 mL). The suspension was vigorously homogenized by vortex, and then cell turbidity was adjusted to 0.5 McFarland scale, which corresponds to 1.5 × 10^6 colony-forming units (CFU)/mL. The resulting suspension obtained was then diluted in Mueller-Hinton broth to achieve the final concentration of 1 × 10^3 CFU/mL.

The minimum inhibitory concentrations (MIC) were determined using MTT colorimetric assay. The MIC is defined as the lowest concentration of an extract to which the microorganism does not demonstrate visible growth by the MTT dye. For the microdilution test, the inoculums of an extract to which the microorganism does not demonstrate visible growth during incubation, growth was indicated by the development of a blue color. To determine the minimum fungicidal concentrations (MFC), 10 µL of broth was taken from each well and incubated in Mueller-Hinton agar at 37°C for 24 h. The MFC was defined as the lowest concentration of extract that resulted in either no growth or fewer than three colonies (99.9% killing).\(^\text{[21]}\) Each test was performed in three replicates and repeated twice. The negative control consisted of 100 µL of the fungus inoculums in 100 µL of DMSO 2.5%, and nystatin (100.000 IU/mL) was used as positive control.

RESULTS
Pharmacognostical characterization

The results of pharmacognostical characterization of C. icaco herbal drug are shown in Table 1. The granulometric analysis indicates that the C. icaco herbal drug is a moderately coarse powder. The values for moisture content, total ash content, and acid-insoluble ash content were within the established limits for herbal drug, according to the Brazilian Pharmacopoeia.\(^\text{[14]}\) The parameters foaming index, content of extractable matter, bulk density, and apparent relative density corresponded to the values for qualitative assays and characterize the herbal drug used in the present work.

| Parameters                              | Mean±SD       |
|-----------------------------------------|---------------|
| Apparent relative density (g/mL)        | 0.457±0.1074  |
| Bulk density (g/mL)                     | 1.010±0.00052 |
| Loss on drying (%)                      | 12.30±0.028   |
| Total ash content (%)                   | 4.31±0.0001   |
| Acid-insoluble ash content (%)          | 1.67±0.0012   |
| Content of extractable matter (%)       | 1.3±0.001     |
| Foaming index                           | 111.11±0.0013 |

Table 1: Pharmacognostical characterization of dry powder of Chrysobalanus icaco leaves

Preliminary phytochemical screening

The phytochemical screening of the HECi indicates the presence of the following metabolic classes: Saponin, reducer sugars, protein and amino acids, tannins, flavonoids, sesquiterpene lactones, triterpenoids and steroids, carotenoids, and depside and depsidone.

Total flavonoid content analysis of hydroalcoholic extract of Chrysobalanus icaco

Using the aluminum complexation reaction, the amount of total flavonoids in HECi was determined as 132,959.33 ± 12,598.23 µg quercetin equivalent/g of extract. Talvez fosse melhor: expressed in quercetin.

High-performance liquid chromatography analysis of hydroalcoholic extract of Chrysobalanus icaco

The HPLC analyses were able to characterize the presence of rutin and myricetin in HECi by comparison of their ultraviolet (UV) spectra [Figure 1a and b] with those obtained from the standard substances. The co-injection of these authentic substances with HECi produces an area increase of the peaks at retention time (RT) of 15.59 and 23.14 min, which confirms the presence of the flavonoids such as rutin and myricetin, respectively, in the extract [Figure 1c and d].

Antifungal activity of the hydroalcoholic extract of Chrysobalanus icaco

Table 2 shows MIC and MFC values of the HECi against different isolates of Candida spp. The HECi was active against clinical isolates of C. albicans and C. parapsilosis with MICs values ranging from of 3.12 to 6.25 mg/mL and MFC above 6.25 mg/mL. On the other hand, the HECi was not active against clinical isolates of C. dubliniensis and C. tropicalis in all concentrations tested. As expected, the HECi exhibited activity against the strain of C. albicans ATCC with MFC of 1.56 mg/mL.

DISCUSSION

Qualitative pharmacognostical parameters encompass a set of physical and phytochemical tests outlined from pharmacopoeias and international guidelines. To characterize the herbal drug obtained from leaves of C. icaco, these parameters were evaluated following the normative requirements for the registration of herbal medicines and are able to predict the purity of raw material and phytochemical constitution of the HECi.\(^\text{[14]}\) The values of pharmacognostical characterization demonstrated that the raw material was correctly processed and stored, and these values were similar to previously determined for total ash content.\(^\text{[22]}\) Concerning to the other pharmacognostical parameters, the powdered leaves of C. icaco showed values which are within the limits set forth in Brazilian Pharmacopoeia.\(^\text{[14]}\) Preliminary phytochemical screening was performed by colorimetric and precipitation reactions aiming to identify some metabolic classes in
In Table 2, the antifungal activity of hydroalcoholic extract of *Chrysobalanus icaco* against oral clinical isolates of *Candida* spp. is presented. Minimum inhibitory concentrations (MIC) and minimum fungicidal concentrations (MFC) are expressed in mg/mL. Inhibition represents the percentage inhibition of growth in the presence of HECi. ND: Not detected. The data indicate a high antifungal activity against oral clinical isolates

### Table 2: Antifungal activity of hydroalcoholic extract of Chrysobalanus icaco against oral clinical isolates of Candida spp.

| Strain   | Species | MIC (mg/mL) | MFC (mg/mL) | Inhibition (%) |
|----------|---------|-------------|-------------|----------------|
| C3       | *C. albicans* | 6.25        | >6.25       | 93             |
| C5       | *C. albicans* | 3.12        | >6.25       | 94             |
| C6       | *C. albicans* | ND          | ND          | 0              |
| C7       | *C. albicans* | ND          | ND          | 0              |
| C2       | *C. parapsilosis* | 3.12     | 6.25        | 100            |
| C4       | *C. parapsilosis* | ND        | ND          | 0              |
| C8       | *C. parapsilosis* | >6.25   | ND          | 40             |
| C9       | *C. parapsilosis* | 6.25      | >6.25       | 59             |
| C10      | *C. parapsilosis* | ND        | ND          | 0              |
| C11      | *C. dubliniensis* | ND        | ND          | 0              |
| C1       | *C. tropicalis* | ND         | ND          | 0              |
| ATCC 40175 | *C. albicans* | <1.56      | 1.56        | 100            |

Inhibition (%) represents the percentage inhibition of growth in the presence of the MFC of HECi. ND: Not detected; MIC: Minimum inhibitory concentrations; MFC: Minimum fungicidal concentrations; *C. albicans*: *Candida albicans*; *C. parapsilosis*: *Candida parapsilosis*; *C. dubliniensis*: *Candida dubliniensis*; HECi: Hydroalcoholic extract of *Chrysobalanus icaco*

Through preliminary phytochemical screening, the presence of classes of compounds already reported in the literature for the species could be identified in the HECi. Barbosa et al.\(^\text{[12]}\) as well as in our study identified the presence of saponins, flavonoids, tannins, catechins, triterpenoids, and steroids. Several compounds have been identified and isolated in preparations obtained from different parts of *C. icaco* including kaurene-type diterpenes, phytosterols (stigmastanol, sitosterol, and campesterol), terpene (Pomolic acid), flavonoid 7-O-methyl kaempferol, catechin, and anthocyanins.\(^\text{[9,10,23]}\)

Flavonoids and terpenes are the major compounds present in *Chrysobalanaceae* species.\(^\text{[24]}\) Using aluminum complexation reaction, the determination of TFC in HECi showed high level, which highlights the majority of these compounds present in *C. icaco*. Among the flavonoids previously reported for *C. icaco*, myricetin figure as its possible phytochemical marker. To verify the presence of this flavonoid as well as the presence of rutin in HECi, HPLC analysis was performed. The chromatographic profile of HECi Figure 1c] compared to that obtained by co-injection of HECi with myricetin and rutin Figure 1d, and the similarity of the UV spectra of HECi corresponding peaks and standards, allowed to conclude that these flavonoids are present in the extract Figure 1a and b, respectively. Several authors have previously reported the identification of both flavonoids in *C. icaco* crude extracts.\(^\text{[6,23,26]}\)

This study also reports the antifungal activity of *C. icaco* against oral clinical isolates of *Candida* spp. obtained from healthy volunteers. HECi exhibited good antifungal activity against some clinical isolates of *C. albicans* and *C. parapsilosis*, but not against *C. dubliniensis* and *C. tropicalis* [Table 2]. On the other hand, other study showed that the methanol and hexane extracts, fractions, and compounds isolated from *C. icaco* did not inhibit different strains of *C. albicans*.\(^\text{[9]}\)

This antifungal action of HECi can be explained by the chemical composition of the extract evaluated. In this regards, myricetin-3-O-β-allopyranoside isolated from hydroalcoholic extract of *Plinia cauliflora* leaves showed antifungal activity against *C. albicans* with MIC and MFC values of 250 and 500 µg/mL, respectively.\(^\text{[27]}\) Shahid also reported the antimicrobial potential of a myricetin derivative against different microorganisms such as seven clinical isolates of *C. albicans* with MFC ranging from 3.9 to 31 µg/mL.\(^\text{[28]}\) Rutin also has been reported showing antifungal activity against *Candida* spp. strains. Araruna et al. reported the antifungal activity of the flavonoid, i.e., rutin against *C. albicans*, *Candida krusei*, and *C. tropicalis* ATCCs with MICs of 32 µg/mL for each strain.\(^\text{[29]}\) Rutin was also able to inhibit the growth of *C. albicans* in a dose-dependent manner (P < 0.01); the concentrations of rutin ranged between 250 and 1000 µg/mL.\(^\text{[30]}\)

Other compounds present in HECi may also be responsible for the antifungal activity such as terpenoids, tannins, and steroids.\(^\text{[31,33]}\) The resistance of *C. dubliniensis* and *C. tropicalis* isolates and some isolates of *C. albicans* and *C. parapsilosis* to the HECi could be explained by the intra- and inter-species genomic variation, which includes differences in virulence factors, for example. According to Cantón et al., there is a variation in the antifungal activity of amphotericin B against different isolates of *Candida* spp. and this is due to the gene variation within the species.\(^\text{[34]}\) As expected from the reported experiments, *C. albicans* ATCC was more sensitive compared to clinical isolates because clinical isolates strains exhibit more genetic variation; consequently, they present major virulence factors.\(^\text{[35]}\)
CONCLUSION

HECI presented antifungal activity against C. albicans and C. parapsilosis clinical isolates, both species with clinical importance in the development of oral candidiasis. The antifungal activity of the HECI may be due to the presence of the flavonoids such as rutin and myricetin in the extract. Furthermore, more investigations are required to assess the possible toxicity and the action mechanism of C. icaco for the development of herbal drugs derived from this species.

Acknowledgments

We are very grateful to Professor Maurimélia Mesquita (in memoriam) for Candida species identification and all support in this work. The authors are also grateful to the Herbarium of the Brazilian Agricultural Research Corporation – Eastern Amazon (EMBRAPA) for plant species identification and to the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), for scientific fellowships. We gratefully acknowledge the financial support of Pró-Reitoria de Pesquisa e Pós-Graduação from UFPA (PROPESP/UFPA).

Financial support and sponsorship

The study was financially supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), for scientific fellowships.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virolence 2013;4:119-28.
2. Singh A, Verma R, Murari A, Agrawal A. Oral candidiasis: An overview. J Oral Maxillofac Pathol 2014;18 Suppl 1:S81-5.
3. Zhang LW, Fu JY, Hua H, Yan ZM. Efficacy and safety of miconazole for oral candidiasis: A systematic review and meta-analysis. Oral Dis 2016;22:185-95.
4. Akpan A, Morgan R. Oral candidiasis. Postgrad Med J 2002;78:455-9.
5. Chen SC, Sorrell TC. Antifungal activity of some cyclooxygenase inhibitors on Candida albicans: PGK2-dependent mechanism. Folia Microbiol (Prag) 2011;56:349-52.
6. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A3. 3rd ed. Wayne: Clinical and Laboratory Standards Institute; 2008.
7. de Quadros AU, Bini D, Pereira MA, Moroni MG, Moniero MC. Antifungal activity of some cyclooxygenase inhibitors on Candida albicans: In vitro studies. J Antimicrob Chemother 2010;65:2013-8.
8. Gustafson KR, Munro MH, Blunt JW, Cardellina JH. PEG-dependent mechanism. Folia Microbiol (Prag) 2011;56:349-52.
9. Aguiar TM. Physical and chemical characteristics of leaves, fruits and seeds of bajurú (Chrysobalanus icaco, L.) and evaluation of these tea leaves in mice (swiss) normal and diabetic [Dissertation]. Seropédica: Federal Rural University of Rio de Janeiro; 2010.
10. Chaffaud M, Emberger L. Traité de Botanique Systematique. Vol. 2. Paris, France; 1960.
11. Gattass CR. Pentacyclic triterpenes from Chrysobalanus icaco. J Nat Prod 2006;69:4547-54.
12. Barbosa AP, Silveira Gde O, de Menezes IA, Rezende Neto JM, Bitencurt J, Estavam Cdos S, et al. Antidiabetic effect of the Chrysobalanus icaco L. aqueous extract in rats. J Med Food 2013;16:538-43.
13. White PA, Cercato LM, Batista VS, Camargo EA, De Lucca W Jr., Oliveira AS, et al. Aqueous extract of Chrysobalanus icaco leaves, in lower doses, prevent fat gain in obese high-fat fed mice. J Ethnopharmacol 2016;179:92-100.
14. Brazil – Brazilian Health Surveillance Agency [ANVISA]. Brazilian Pharmacopeia, 5th ed. Brasília. Fasicule 1. 2010
15. World Health Organization. Quality Control Methods for Medicinal Plant Materials. Update Edition. Geneva: WHO; 2011.
16. Costa A, Proença F, Cunha A. Farmacognosia. 3rd ed. Lisboa: Calouste Gulbenkian; 2000.
17. bikeletal. eds. A. Pyrzynska K. Evaluation of aluminium complexation reaction for flavonoid content assay. Food Anal Methods 2014;7:1778-82.
18. Byadarahally Raju S, Raiappa S. Isolation and identification of Candida from the oral cavity. ISRN Dent 2011;2011:487921.
19. Chrysobalanus icaco (L.) as... Brazilian Pharmacopeia, 5th ed. Brasília. Fasicule 1. 2010
20. Lee County Extension. Brown SH. Chrysobalanus icaco Available from: http://www.lee.ifas.ufl.edu/Hort/GardenPubsA2/Cocopium_Chrysobalanus_icaco.pdf. Last cited on 2015 Dec 12).
21. Barbosa WL, Peres A, Gallori S, Vincieri FF. Determination of myricetin and flavonoids in fruits of selected tropical fruits: Acerola, jambolão, jussara, and gualuuru. J Agric Food Chem 2007;55:9389-94.
22. Fernandez J, Castilho RO, da Costa MR, Wagner-Souza K, Coelho Kaplan MA, Gattass CR. Pentacyclic triterpenes from Chrysobalanaceae species: Cytoxic toxicity on multidrug resistant and sensitive leukemia cell lines. Cancer Lett 2003;190:165-9.
23. Barbosa AP, Silveira Gde O, de Menezes IA, Rezende Neto JM, Bitencurt J, Estavam Cdos S, et al. Antidiabetic effect of the Chrysobalanus icaco L. aqueous extract in rats. J Med Food 2013;16:538-43.
24. White PA, Cercato LM, Batista VS, Camargo EA, De Lucca W Jr., Oliveira AS, et al. Aqueous extract of Chrysobalanus icaco leaves, in lower doses, prevent fat gain in obese high-fat fed mice. J Ethnopharmacol 2016;179:92-100.
25. Brazil – Brazilian Health Surveillance Agency [ANVISA]. Brazilian Pharmacopeia, 5th ed. Brasília. Fasicule 1. 2010
26. World Health Organization. Quality Control Methods for Medicinal Plant Materials. Update Edition. Geneva: WHO; 2011.
27. Costa A, Proença F, Cunha A. Farmacognosia. 3rd ed. Lisboa: Calouste Gulbenkian; 2000.
28. bikeletal. eds. A. Pyrzynska K. Evaluation of aluminium complexation reaction for flavonoid content assay. Food Anal Methods 2014;7:1778-82.
29. Byadarahally Raju S, Raiappa S. Isolation and identification of Candida from the oral cavity. ISRN Dent 2011;2011:487921.
30. Chrysobalanus icaco (L.) as... Brazilian Pharmacopeia, 5th ed. Brasília. Fasicule 1. 2010
31. Lee County Extension. Brown SH. Chrysobalanus icaco Available from: http://www.lee.ifas.ufl.edu/Hort/GardenPubsA2/Cocopium_Chrysobalanus_icaco.pdf. Last cited on 2015 Dec 12).
32. Barbosa WL, Peres A, Gallori S, Vincieri FF. Determination of myricetin and flavonoids in fruits of selected tropical fruits: Acerola, jambolão, jussara, and gualuuru. J Agric Food Chem 2007;55:9389-94.
33. Fernandez J, Castilho RO, da Costa MR, Wagner-Souza K, Coelho Kaplan MA, Gattass CR. Pentacyclic triterpenes from Chrysobalanaceae species: Cytoxic toxicity on multidrug resistant and sensitive leukemia cell lines. Cancer Lett 2003;190:165-9.
34. Barbosa AP, Silveira Gde O, de Menezes IA, Rezende Neto JM, Bitencurt J, Estavam Cdos S, et al. Antidiabetic effect of the Chrysobalanus icaco L. aqueous extract in rats. J Med Food 2013;16:538-43.